{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T20:45:47Z","timestamp":1787604347704,"version":"build-2736575974"},"reference-count":32,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100018937","name":"Bavarian Nordic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018937","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.vaccine.2020.01.058","type":"journal-article","created":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T16:58:59Z","timestamp":1581440339000},"page":"2600-2607","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":71,"title":["A randomized phase II trial to compare safety and immunogenicity of the MVA-BN smallpox vaccine at various doses in adults with a history of AIDS"],"prefix":"10.1016","volume":"38","author":[{"given":"Edgar Turner","family":"Overton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven J.","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack T.","family":"Stapleton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Weidenthaler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darja","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Koenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnter","family":"Silbernagl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Nopora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Chaplin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2020.01.058_b0005","doi-asserted-by":"crossref","first-page":"257","DOI":"10.15585\/mmwr.mm6510a2","article-title":"Use of Vaccinia Virus Smallpox Vaccine in Laboratory and Health Care Personnel at Risk for Occupational Exposure to Orthopoxviruses - Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2015","volume":"65","author":"Petersen","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2020.01.058_b0010","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1093\/aje\/kwh269","article-title":"Myopericarditis following smallpox vaccination","volume":"160","author":"Arness","year":"2004","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2020.01.058_b0015","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1093\/infdis\/122.4.303","article-title":"Complications of smallpox vaccination, 1968: results of ten statewide surveys","volume":"122","author":"Lane","year":"1970","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.01.058_b0020","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJM196911272812201","article-title":"Complications of smallpox vaccination, 1968","volume":"281","author":"Lane","year":"1969","journal-title":"New Engl J Med"},{"key":"10.1016\/j.vaccine.2020.01.058_b0025","doi-asserted-by":"crossref","first-page":"3283","DOI":"10.1001\/jama.289.24.3283","article-title":"Myopericarditis following smallpox vaccination among vaccinia-naive US military personnel","volume":"289","author":"Halsell","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2020.01.058_b0030","first-page":"1","article-title":"Advisory Committee on Immunization P. Vaccinia (smallpox) vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2001","volume":"50","author":"Rotz","year":"2001","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2020.01.058_b0035","first-page":"1","article-title":"Clinical guidance for smallpox vaccine use in a postevent vaccination program","volume":"64","author":"Petersen","year":"2015","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2020.01.058_b0040","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1093\/cid\/cit684","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"Suppl 3","key":"10.1016\/j.vaccine.2020.01.058_b0045","first-page":"s2","article-title":"British HIV Association Guidelines on the Use of Vaccines in HIV-Positive Adults 2015","volume":"17","author":"Geretti","year":"2016","journal-title":"HIV Med"},{"key":"10.1016\/j.vaccine.2020.01.058_b0050","first-page":"1","article-title":"Recommendations for using smallpox vaccine in a pre-event vaccination program. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices Advisory Committee (HICPAC)","volume":"52","author":"Wharton","year":"2003","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2020.01.058_b0055","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1001\/archderm.1990.01670320057007","article-title":"Varicella in patients infected with the human immunodeficiency virus","volume":"126","author":"Perronne","year":"1990","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.vaccine.2020.01.058_b0060","doi-asserted-by":"crossref","first-page":"8562","DOI":"10.1016\/j.vaccine.2007.10.017","article-title":"Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax challenge","volume":"25","author":"Frey","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.01.058_b0065","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1817307","article-title":"Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against Smallpox","volume":"381","author":"Pittman","year":"2019","journal-title":"New Engl J Med"},{"key":"10.1016\/j.vaccine.2020.01.058_b0070","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.vaccine.2009.11.030","article-title":"A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE","volume":"28","author":"von Krempelhuber","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.01.058_b0075","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1016\/j.vaccine.2014.02.043","article-title":"Phase II randomized, double-blinded comparison of a single high dose (5x10(8) TCID50) of modified vaccinia Ankara compared to a standard dose (1x10(8) TCID50) in healthy vaccinia-naive individuals","volume":"32","author":"Frey","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.01.058_b0080","doi-asserted-by":"crossref","first-page":"e0157335","DOI":"10.1371\/journal.pone.0157335","article-title":"A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN(R)) in 56\u201380-Year-Old Subjects","volume":"11","author":"Greenberg","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2020.01.058_b0085","doi-asserted-by":"crossref","first-page":"5225","DOI":"10.1016\/j.vaccine.2015.06.075","article-title":"Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naive subjects","volume":"33","author":"Frey","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.01.058_b0090","doi-asserted-by":"crossref","first-page":"e0122653","DOI":"10.1371\/journal.pone.0122653","article-title":"Cardiac safety of Modified Vaccinia Ankara for vaccination against smallpox in a young, healthy study population","volume":"10","author":"Zitzmann-Roth","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2020.01.058_b0095","doi-asserted-by":"crossref","first-page":"e0195897","DOI":"10.1371\/journal.pone.0195897","article-title":"Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial","volume":"13","author":"Overton","year":"2018","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2020.01.058_b0100","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1016\/j.vaccine.2013.04.050","article-title":"Safety and immunogenicity of IMVAMUNE(R) smallpox vaccine using different strategies for a post event scenario","volume":"31","author":"Frey","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.01.058_b0105","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/j.vaccine.2005.11.022","article-title":"Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine","volume":"24","author":"Vollmar","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.01.058_b0110","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1099\/vir.0.010553-0","article-title":"Evaluation of smallpox vaccines using variola neutralization","volume":"90","author":"Damon","year":"2009","journal-title":"J General Virol"},{"key":"10.1016\/j.vaccine.2020.01.058_b0115","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1093\/infdis\/jit105","article-title":"Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial","volume":"207","author":"Walsh","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.01.058_b0120","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/infdis\/jis753","article-title":"Safety, immunogenicity, and surrogate markers of clinical efficacy for modified vaccinia Ankara as a smallpox vaccine in HIV-infected subjects","volume":"207","author":"Greenberg","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.01.058_b0125","doi-asserted-by":"crossref","first-page":"ofv040","DOI":"10.1093\/ofid\/ofv040","article-title":"Safety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label, Controlled Clinical Phase II Trial","volume":"2","author":"Overton","year":"2015","journal-title":"Open Forum Infectious Diseases"},{"key":"10.1016\/j.vaccine.2020.01.058_b0130","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/IPC.0b013e31815c5e6e","article-title":"Routine Vaccination in HIV-Infected Adults","volume":"16","author":"Landrum","year":"2008","journal-title":"Infectious Diseases Clin Practice"},{"key":"10.1016\/j.vaccine.2020.01.058_b0135","doi-asserted-by":"crossref","first-page":"7442","DOI":"10.1016\/j.vaccine.2009.05.095","article-title":"Modified vaccinia Ankara strains with identical coding sequences actually represent complex mixtures of viruses that determine the biological properties of each strain","volume":"27","author":"Suter","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.01.058_b0140","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.jacc.2003.11.053","article-title":"Smallpox vaccination and myopericarditis: a clinical review","volume":"43","author":"Cassimatis","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.vaccine.2020.01.058_b0145","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jacc.2004.05.004","article-title":"Incidence and follow-up of inflammatory cardiac complications after smallpox vaccination","volume":"44","author":"Eckart","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.vaccine.2020.01.058_b0150","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1056\/NEJM200204253461713","article-title":"The case for voluntary smallpox vaccination","volume":"346","author":"Bicknell","year":"2002","journal-title":"New Engl J Med"},{"key":"10.1016\/j.vaccine.2020.01.058_b0155","unstructured":"Acambis. ACAM2000 Smallpox Vaccine. In: Committee VaRBPA, editor. Food and Drug Administration: Food and Drug Administration; 2007. p. 1\u201370."},{"key":"10.1016\/j.vaccine.2020.01.058_b0160","doi-asserted-by":"crossref","first-page":"214","DOI":"10.4269\/ajtmh.1972.21.214","article-title":"A prospective study of serum antibody and protection against smallpox","volume":"21","author":"Mack","year":"1972","journal-title":"Am J Trop Med Hygiene"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20300852?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20300852?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:41:45Z","timestamp":1759401705000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20300852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S0264410X20300852"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.01.058","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A randomized phase II trial to compare safety and immunogenicity of the MVA-BN smallpox vaccine at various doses in adults with a history of AIDS","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.01.058","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}